
Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy Protagonist Therapeutics (PTGX) Stock
Start investing in Protagonist Therapeutics (PTGX)
About Protagonist Therapeutics (PTGX)
Market cap | $3.43B |
Today's volume | 643.78K |
Revenue (TTM) | $207.8M |
Avg. daily volume | 1.04M |
EBITDA (TTM) | $29.61M |
Open | $55.57 |
Price / earnings ratio | 72.66x |
Today's range | $50.61 - $55.68 |
Debt / equity | 1.65x |
52 week range | $32.5 - $60.6 |
5 year debt / equity | 0.98x |
Beta (LTM) | 0.36x |
Interest coverage | — |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 17.26x |
Ex-dividend date | — |
Next earnings | Aug 5, 2025 |
Dividend payable date | — |
Protagonist Therapeutics Stock Rating
Protagonist Therapeutics Stock News
View all



Frequently Asked Questions (FAQ)
How to buy PTGX stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in PTGX stock
Navigate to the Explore page. Then, type PTGX into the search bar. When you see PTGX stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased PTGX stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
Protagonist Therapeutics Stock Earnings
The value each PTGX share was expected to gain vs. the value that each PTGX share actually gained.
Protagonist Therapeutics (PTGX) reported Q1 2025 earnings per share (EPS) of -$0.19, missing estimates of $0.11 by 272.73%. In the same quarter last year, Protagonist Therapeutics's earnings per share (EPS) was $3.26. Protagonist Therapeutics is expected to release next earnings on 08/05/2025, with an earnings per share (EPS) estimate of -$0.50.